SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014

[June 10, 2014]

Research and Markets: Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/dzrt4d/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects.

The report features investigational drugs rom across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.


Drug profiles/records featured in the report undergo periodic updating following a stringent set of processes that ensure all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned:

  • Hospira, Inc.
  • Athersys, Inc.
  • GlaxoSmithKline plc
  • BioLineRx, Ltd.
  • Novartis AG
  • Celldex Therapeutics, Inc.
  • Antisense Therapeutics Limited
  • Actinium Pharmaceuticals, Inc.
  • Pharmalink AB
  • Recoly N.V.
  • Polyphor Ltd.
  • Kiadis Pharma B.V.
  • Bellicum Pharmaceuticals, Inc.
  • TaiGen Biotechnology Co., Ltd.
  • TikoMed AB
  • Tarix Pharmaceuticals LTD.

For more information visit http://www.researchandmarkets.com/research/dzrt4d/hematopoietic


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.